Nektar Therapeutics
- Last sale
- Nov 12, 2026 · -2.76%
- Market cap
- $1.28B
- 34.21M shares
- Filings
- 1,046
Q3 2026−43.9% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derivedN/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026−65.8% FY25 yoy
- $1.28B
- —
- 24.4×
- 1.5×
- -20.18%
- —
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of record
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $55,232,000 | reported | |
| FY 2024 | 2024-12-31 | $98,427,000 | reported | |
| FY 2023 | 2023-12-31 | $90,122,000 | reported | |
| FY 2022 | 2022-12-31 | $92,055,000 | reported | |
| FY 2021 | 2021-12-31 | $101,907,000 | reported | |
| FY 2020 | 2020-12-31 | $152,915,000 | reported | |
| FY 2019 | 2019-12-31 | $114,617,000 | reported | |
| FY 2018 | 2018-12-31 | $1,193,323,000 | reported | |
| FY 2017 | 2017-12-31 | $307,711,000 | reported | |
| FY 2016 | 2016-12-31 | $165,436,000 | reported | |
| FY 2015 | 2015-12-31 | $230,784,000 | reported | |
| FY 2014 | 2014-12-31 | $200,707,000 | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2025 | — | $0.00 | $0.00 | — | 28.69M sh | −84.6% | — |
| FY2024 | — | $3.00M | $3.00M | — | 186.10M sh | +1.4% | — |
| FY2023 | — | $0.00 | $0.00 | — | 183.62M sh | −3.0% | — |
Segments
LineFY2021ShareChange
United States$56.10M93%+2.9%
India$4.40M7.3%−13.7%
Total$60.51M
Pharmaceutical preparations
Nektar Therapeutics is the 124th largest of the 552 covered companies the SEC files under this code, by revenue. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
NUVBNuvation Bio Inc.$62.9M699.0%325.3%$1.4BTNGXTango Therapeutics, Inc.$62.4M48.3%162.9%$4.2BDERMJourney Medical Corp$61.9M10.2%18.5%$123.4MAYTUAytu Biopharma, Inc$57.6M13.3%24.8%$19.4M
NKTRNektar Therapeutics (this company)$55.2M43.9%297.1%$1.3B
AGIOAgios Pharmaceuticals, Inc.$54.0M48.0%764.0%$1.9BQTTBQ32 Bio Inc.$53.7M—55.5%$263.3MOCULOcular Therapeutix, Inc$52.0M18.5%511.9%$1.4BLXRXLexicon Pharmaceuticals, Inc.$49.8M729.9%101.1%$812.6MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Nektar Therapeutics · CIK 906709 · Engraved from SEC EDGAR